CONMED (CNMD) 10-Q 30 Jul 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Jul. 27, 2020
Cover [Abstract]
Entity Incorporation, State or Country Code	DE
Entity Registrant Name	CONMED CORPORATION
City Area Code	315
Local Phone Number	797-8375
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Central Index Key	0000816956
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Small Business	false
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Amendment Flag	false
Title of 12(b) Security	Common Stock, $0.01 par value
Entity Common Stock, Shares Outstanding		28,571,386
Entity File Number	001-39218
Entity Tax Identification Number	16-0977505
Entity Address, Address Line One	525 French Road
Entity Address, City or Town	Utica,
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	13502
Trading Symbol	CNMD
Security Exchange Name	NYSE

Consolidated Condensed Statemen

Consolidated Condensed Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Statement of Comprehensive Income [Abstract]
Net sales	$ 157,785	$ 238,263	$ 371,796	$ 456,641
Cost of sales	85,856	107,073	180,707	204,013
Gross profit	71,929	131,190	191,089	252,628
Selling and administrative expense	84,475	100,726	180,343	199,952
Research and development expense	8,700	11,806	18,820	22,381
Operating expenses	93,175	112,532	199,163	222,333
Income (loss) from operations	(21,246)	18,658	(8,074)	30,295
Interest expense	11,401	11,839	20,993	21,208
Other expense	89	321	178	4,546
Income (loss) before income taxes	(32,736)	6,498	(29,245)	4,541
Provision (benefit) for income taxes	(5,336)	803	(7,772)	(2,175)
Net income (loss)	(27,400)	5,695	(21,473)	6,716
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	$ (24,713)	$ 5,751	$ (25,834)	$ 6,847
Per share data:
Basic (in dollars per share)	$ (0.96)	$ 0.20	$ (0.75)	$ 0.24
Diluted (in dollars per share)	$ (0.96)	$ 0.19	$ (0.75)	$ 0.23
Weighted average common shares:
Basic (shares)	28,542	28,276	28,506	28,228
Diluted (shares)	28,542	29,337	28,506	29,197

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 34,983	$ 25,856
Accounts receivable, net	143,412	189,097
Inventories	175,715	164,616
Prepaid expenses and other current assets	24,603	17,794
Total current assets	378,713	397,363
Property, plant and equipment, net	113,164	118,883
Goodwill	616,685	618,042
Other intangible assets, net	517,187	532,800
Other assets	98,159	108,007
Total assets	1,723,908	1,775,095
Current liabilities:
Current portion of long-term debt	15,193	13,596
Accounts payable	39,831	55,968
Accrued compensation and benefits	36,822	53,690
Other current liabilities	58,766	64,833
Total current liabilities	150,612	188,087
Long-term debt	790,425	755,211
Deferred income taxes	64,935	74,488
Other long-term liabilities	43,038	46,842
Total liabilities	1,049,010	1,064,628
Commitments and contingencies
Shareholders' equity:
Preferred stock, par value $.01 per share; authorized 500,000 shares; none outstanding	0	0
Common stock, par value $0.01 per share; 100,000,000 shares authorized; 31,299,194 shares issued in 2020 and 2019, respectively	313	313
Paid-in capital	377,025	379,324
Retained earnings	437,956	470,844
Accumulated other comprehensive loss	(63,638)	(59,277)
Less: 2,734,967 and 2,876,729 shares of common stock in treasury, at cost in 2020 and 2019, respectively	(76,758)	(80,737)
Total shareholders’ equity	674,898	710,467
Total liabilities and shareholders’ equity	$ 1,723,908	$ 1,775,095

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value (dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	500,000	500,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	31,299,194	31,299,194
Treasury stock, shares (in shares)	2,734,967	2,876,729

Consolidated Condensed Statem_2

Consolidated Condensed Statements of Shareholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Stock
Balance at period start (shares) at Dec. 31, 2018		31,299
Balance at period start at Dec. 31, 2018	$ 662,270	$ 313	$ 341,738	$ 464,851	$ (55,737)	$ (88,895)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued under employee plans	1,748		(769)			2,517
Stock-based compensation	2,703		2,703
Dividends on common stock ($0.20 per share)	(5,643)			(5,643)
Convertible notes discount (net of income tax expense)	39,145		39,145
Convertible notes hedge, (net of income tax benefit)	(38,829)		(38,829)
Issuance of warrants	30,567		30,567
Comprehensive income (loss):
Foreign currency translation adjustments					(578)
Pension liability, net of income tax					547
Cash flow hedging gain (loss), net of income tax					106
Net income (loss)				1,021
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	1,096
Balance at period end (shares) at Mar. 31, 2019		31,299
Balance at period end at Mar. 31, 2019	693,057	$ 313	374,555	460,229	(55,662)	(86,378)
Balance at period start (shares) at Dec. 31, 2018		31,299
Balance at period start at Dec. 31, 2018	662,270	$ 313	341,738	464,851	(55,737)	(88,895)
Comprehensive income (loss):
Foreign currency translation adjustments	530
Pension liability, net of income tax	1,093
Cash flow hedging gain (loss), net of income tax	(1,492)
Net income (loss)	6,716
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	6,847
Balance at period end (shares) at Jun. 30, 2019		31,299
Balance at period end at Jun. 30, 2019	697,009	$ 313	376,519	460,267	(55,606)	(84,484)
Balance at period start (shares) at Mar. 31, 2019		31,299
Balance at period start at Mar. 31, 2019	693,057	$ 313	374,555	460,229	(55,662)	(86,378)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued under employee plans	750		(1,144)			1,894
Stock-based compensation	3,108		3,108
Dividends on common stock ($0.20 per share)	(5,657)			(5,657)
Comprehensive income (loss):
Foreign currency translation adjustments	1,108				1,108
Pension liability, net of income tax	546				546
Cash flow hedging gain (loss), net of income tax	(1,598)				(1,598)
Net income (loss)	5,695			5,695
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	5,751
Balance at period end (shares) at Jun. 30, 2019		31,299
Balance at period end at Jun. 30, 2019	697,009	$ 313	376,519	460,267	(55,606)	(84,484)
Balance at period start (shares) at Dec. 31, 2019		31,299
Balance at period start at Dec. 31, 2019	710,467	$ 313	379,324	470,844	(59,277)	(80,737)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued under employee plans	(5,040)		(7,736)			2,696
Stock-based compensation	3,032		3,032
Dividends on common stock ($0.20 per share)	(5,703)			(5,703)
Comprehensive income (loss):
Foreign currency translation adjustments					(9,988)
Pension liability, net of income tax					535
Cash flow hedging gain (loss), net of income tax					2,405
Net income (loss)				5,927
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	(1,121)
Balance at period end (shares) at Mar. 31, 2020		31,299
Balance at period end at Mar. 31, 2020	701,635	$ 313	374,620	471,068	(66,325)	(78,041)
Balance at period start (shares) at Dec. 31, 2019		31,299
Balance at period start at Dec. 31, 2019	710,467	$ 313	379,324	470,844	(59,277)	(80,737)
Comprehensive income (loss):
Foreign currency translation adjustments	(5,407)
Pension liability, net of income tax	1,070
Cash flow hedging gain (loss), net of income tax	(24)
Net income (loss)	(21,473)			(21,473)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	(25,834)
Balance at period end (shares) at Jun. 30, 2020		31,299
Balance at period end at Jun. 30, 2020	674,898	$ 313	377,025	437,956	(63,638)	(76,758)
Balance at period start (shares) at Mar. 31, 2020		31,299
Balance at period start at Mar. 31, 2020	701,635	$ 313	374,620	471,068	(66,325)	(78,041)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued under employee plans	133		(1,150)			1,283
Stock-based compensation	3,555		3,555
Dividends on common stock ($0.20 per share)	(5,712)			(5,712)
Comprehensive income (loss):
Foreign currency translation adjustments	4,581				4,581
Pension liability, net of income tax	535				535
Cash flow hedging gain (loss), net of income tax	(2,429)				(2,429)
Net income (loss)	(27,400)			(27,400)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	(24,713)
Balance at period end (shares) at Jun. 30, 2020		31,299
Balance at period end at Jun. 30, 2020	$ 674,898	$ 313	$ 377,025	$ 437,956	$ (63,638)	$ (76,758)

Consolidated Condensed Statem_3

Consolidated Condensed Statements of Shareholders' Equity (Parenthetical) - $ / shares	3 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019
Dividends per share of common stock (in dollars per share)	$ 0.20	$ 0.20	$ 0.20	$ 0.20

Consolidated Condensed Statem_4

Consolidated Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities:
Net income (loss)	$ (21,473)	$ 6,716
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation	9,234	8,967
Amortization of debt discount	4,810	3,774
Amortization of deferred debt issuance costs	1,686	1,616
Amortization	27,392	25,460
Stock-based compensation	6,587	5,811
Deferred income taxes	(9,490)	(6,254)
Loss on early extinguishment of debt	0	300
Increase (decrease) in cash flows from changes in assets and liabilities:
Accounts receivable	43,732	6,935
Inventories	(13,029)	(13,809)
Accounts payable	(15,703)	(5,078)
Accrued compensation and benefits	(16,646)	(6,979)
Other assets	(3,634)	(13,939)
Other liabilities	(4,206)	4,137
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities	30,733	10,941
Net cash provided by operating activities	9,260	17,657
Cash flows from investing activities:
Purchases of property, plant and equipment	(6,577)	(9,006)
Payments related to business and asset acquisitions, net of cash acquired	(3,852)	(364,928)
Net cash used in investing activities	(10,429)	(373,934)
Cash flows from financing activities:
Payments on term loan	(6,625)	(147,688)
Proceeds from term loan	0	265,000
Payments on revolving line of credit	(70,000)	(393,000)
Proceeds from revolving line of credit	108,000	343,000
Proceeds from convertible notes	0	345,000
Payments related to contingent consideration	(2,071)	(4,405)
Payments related to debt issuance costs	(2,057)	(16,210)
Dividends paid on common stock	(11,387)	(11,269)
Purchases of convertible notes hedges	0	(51,198)
Proceeds from issuance of warrants	0	30,567
Other, net	(5,090)	1,482
Net cash provided by financing activities	10,770	361,279
Effect of exchange rate changes on cash and cash equivalents	(474)	36
Net increase in cash and cash equivalents	9,127	5,038
Cash and cash equivalents at beginning of period	25,856	17,511
Cash and cash equivalents at end of period	34,983	22,549
Non-cash investing and financing activities:
Dividends payable	$ 5,712	$ 5,657

Operations

Operations	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Operations	OperationsCONMED Corporation (“CONMED”, the “Company”, “we” or “us”) is a medical technology company that provides surgical devices and equipment for minimally invasive procedures.  The Company’s products are used by surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery, thoracic surgery and gastroenterology.

Interim Financial Information

Interim Financial Information	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Interim financial information	Interim Financial Information The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for annual financial statements. The information herein reflects all normal recurring material adjustments, which are, in the opinion of management, necessary to fairly present the results for the periods presented. The consolidated condensed financial statements herein consist of all wholly-owned domestic and foreign subsidiaries with all significant intercompany transactions eliminated. Results for the period ended June 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020. The consolidated condensed financial statements and notes thereto should be read in conjunction with the consolidated financial statements and notes for the year ended December 31, 2019 included in our Annual Report on Form 10-K. Use of Estimates Preparation of the consolidated condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated condensed financial statements and the reported amounts of revenue and expenses during the reporting period. Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. We are not aware of any specific event or circumstance that would require an update to our estimates or judgments or a revision of the carrying value of our assets or liabilities as of July 30, 2020, the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change, as new events occur and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions.

Business Acquisition

Business Acquisition	6 Months Ended
	Jun. 30, 2020
Business Combinations [Abstract]
Business Acquisition	Business Acquisition On February 11, 2019 we acquired Buffalo Filter, LLC and all of the issued and outstanding common stock of Palmerton Holdings, Inc. from Filtration Group FGC LLC (the "Buffalo Filter Acquisition") for approximately $365 million in cash. Buffalo Filter develops, manufactures and markets smoke evacuation technologies that are complementary to our general surgery offering. The business combination was funded through a combination of cash on hand and long-term borrowings. The unaudited pro forma information for the three and six months ended June 30, 2019, assuming the Buffalo Filter Acquisition occurred as of January 1, 2018 are presented below. This information has been prepared for comparative purposes only and does not purport to be indicative of the results of operations which actually would have resulted had the Buffalo Filter Acquisition occurred on the dates indicated, or which may result in the future. Three Months Ended June 30, Six Months Ended June 30, 2019 2019 Net sales $ 238,263 $ 461,660 Net income 8,625 17,370 These pro forma results include certain adjustments, primarily due to increases in amortization expense due to fair value adjustments of intangible assets, increases in interest expense due to additional borrowings incurred to finance the acquisition and amortization of debt issuance costs incurred to finance the transaction, and acquisition related costs including transaction costs such as legal, accounting, valuation and other professional services as well as integration costs such as severance and retention. Acquisition related costs excluded from the determination of pro forma net income for the three months ended June 30, 2019 were $0.5 million in cost of goods sold and $2.5 million in selling and administrative expense and for the six months ended June 30, 2019 were $1.2 million in cost of goods sold and $9.7 million in selling and administrative expense on the consolidated condensed statements of comprehensive income. Net sales associated with Buffalo Filter of $13.5 million and $19.5 million have been recorded in the consolidated condensed statements of comprehensive income for the three and six months ended June 30, 2019, respectively. It is impracticable to determine the earnings recorded in the consolidated condensed statements of comprehensive income for the three and six months ended June 30, 2019 as these amounts are not separately measured. In conjunction with the December 2019 acquisition of a distributor, we paid $3.8 million during the six months ended June 30, 2020.

Revenues

Revenues	6 Months Ended
	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Revenues	Revenues The following tables present revenue disaggregated by primary geographic market where the products are sold, by product line and timing of revenue recognition: Three Months Ended Three Months Ended June 30, 2020 June 30, 2019 Orthopedic Surgery General Surgery Total Orthopedic Surgery General Surgery Total Primary Geographic Markets United States $ 21,387 $ 66,038 $ 87,425 $ 43,335 $ 85,601 $ 128,936 Americas (excluding the United States) 5,582 4,637 10,219 15,781 7,823 23,604 Europe, Middle East & Africa 13,715 16,146 29,861 31,099 15,763 46,862 Asia Pacific 19,799 10,481 30,280 25,542 13,319 38,861 Total sales from contracts with customers $ 60,483 $ 97,302 $ 157,785 $ 115,757 $ 122,506 $ 238,263 Timing of Revenue Recognition Goods transferred at a point in time $ 53,670 $ 96,422 $ 150,092 $ 106,772 $ 121,927 $ 228,699 Services transferred over time 6,813 880 7,693 8,985 579 9,564 Total sales from contracts with customers $ 60,483 $ 97,302 $ 157,785 $ 115,757 $ 122,506 $ 238,263 Six Months Ended Six Months Ended June 30, 2020 June 30, 2019 Orthopedic Surgery General Surgery Total Orthopedic Surgery General Surgery Total Primary Geographic Markets United States $ 58,426 $ 147,847 $ 206,273 $ 88,590 $ 157,371 $ 245,961 Americas (excluding the United States) 21,385 12,617 34,002 30,823 15,286 46,109 Europe, Middle East & Africa 39,622 32,761 72,383 61,505 31,688 93,193 Asia Pacific 40,333 18,805 59,138 48,276 23,102 71,378 Total sales from contracts with customers $ 159,766 $ 212,030 $ 371,796 $ 229,194 $ 227,447 $ 456,641 Timing of Revenue Recognition Goods transferred at a point in time $ 144,222 $ 210,324 $ 354,546 $ 211,511 $ 226,351 $ 437,862 Services transferred over time 15,544 1,706 17,250 17,683 1,096 18,779 Total sales from contracts with customers $ 159,766 $ 212,030 $ 371,796 $ 229,194 $ 227,447 $ 456,641 Contract liability balances related to the sale of extended warranties to customers are as follows: June 30, 2020 December 31, 2019 Contract liability $ 13,251 $ 14,276 Revenue recognized during the six months ended June 30, 2020 and June 30, 2019 from amounts included in contract liabilities at the beginning of the period were $5.5 million and $4.0 million, respectively. There were no material contract assets as of June 30, 2020 and December 31, 2019.

Comprehensive Income (Loss)

Comprehensive Income (Loss)	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Comprehensive Income (Loss)	Comprehensive Income (loss) Comprehensive income (loss) consists of the following: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Net income (loss) $ (27,400) $ 5,695 $ (21,473) $ 6,716 Other comprehensive income (loss): Pension liability, net of income tax (income tax expense of $170 and $174 for the three months ended June 30, 2020 and 2019, respectively, and $340 and $347 for the six months ended June 30, 2020 and 2019, respectively) 535 546 1,070 1,093 Cash flow hedging loss, net of income tax (income tax benefit of $774 and $509 for the three months ended June 30, 2020 and 2019, respectively, and $8 and $475 for the six months ended June 30, 2020 and 2019, respectively) (2,429) (1,598) (24) (1,492) Foreign currency translation adjustment 4,581 1,108 (5,407) 530 Comprehensive income (loss) $ (24,713) $ 5,751 $ (25,834) $ 6,847 Accumulated other comprehensive loss consists of the following: Cash Flow Pension Cumulative Accumulated Balance, December 31, 2019 $ 493 $ (31,691) $ (28,079) $ (59,277) Other comprehensive income (loss) before reclassifications, net of tax 770 — (5,407) (4,637) Amounts reclassified from accumulated other comprehensive income (loss) before tax a (1,048) 1,410 — 362 Income tax 254 (340) — (86) Net current-period other comprehensive income (loss) (24) 1,070 (5,407) (4,361) Balance, June 30, 2020 $ 469 $ (30,621) $ (33,486) $ (63,638) Cash Flow Pension Cumulative Accumulated Balance, December 31, 2018 $ 4,085 $ (31,718) $ (28,104) $ (55,737) Other comprehensive income (loss) before reclassifications, net of tax 1,414 — 530 1,944 Amounts reclassified from accumulated other comprehensive income (loss) before tax a (3,832) 1,440 — (2,392) Income tax 926 (347) — 579 Net current-period other comprehensive income (loss) (1,492) 1,093 530 131 Balance, June 30, 2019 $ 2,593 $ (30,625) $ (27,574) $ (55,606) (a) The cash flow hedging gain (loss) and pension liability accumulated other comprehensive income (loss) components are included in sales or cost of sales and as a component of net periodic pension cost, respectively. Refer to Note 6 and Note 12, respectively, for further details.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments We enter into derivative instruments for risk management purposes only. We operate internationally and, in the normal course of business, are exposed to fluctuations in interest rates, foreign exchange rates and commodity prices. These fluctuations can increase the costs of financing, investing and operating the business. We use forward contracts, a type of derivative instrument, to manage certain foreign currency exposures. By nature, all financial instruments involve market and credit risks. We enter into forward contracts with major investment grade financial institutions and have policies to monitor the credit risk of those counterparties. While there can be no assurance, we do not anticipate any material non-performance by any of these counterparties. Foreign Currency Forward Contracts. We hedge forecasted intercompany sales denominated in foreign currencies through the use of forward contracts. We account for these forward contracts as cash flow hedges. To the extent these forward contracts meet hedge accounting criteria, changes in their fair value are not included in current earnings but are included in accumulated other comprehensive loss. These changes in fair value will be recognized into earnings as a component of sales or cost of sales when the forecasted transaction occurs. We also enter into forward contracts to exchange foreign currencies for United States dollars in order to hedge our currency transaction exposures on intercompany receivables designated in foreign currencies. These forward contracts settle each month at month-end, at which time we enter into new forward contracts. We have not designated these forward contracts as hedges and have not applied hedge accounting to them. The following table presents the notional contract amounts for forward contracts outstanding: As of FASB ASC Topic 815 Designation June 30, 2020 December 31, 2019 Forward exchange contracts Cash flow hedge $ 122,556 $ 156,818 Forward exchange contracts Non-designated 37,901 33,867 The remaining time to maturity as of June 30, 2020 is within two years for hedge designated foreign exchange contracts and approximately one month for non-hedge designated forward exchange contracts. Statement of comprehensive income (loss) presentation Derivatives designated as cash flow hedges Foreign exchange contracts designated as cash flow hedges had the following effects on accumulated other comprehensive income (loss) and net earnings on our consolidated condensed statements of comprehensive income (loss) and our consolidated condensed balance sheets: Amount of Gain (Loss) Recognized in AOCI Consolidated Condensed Statements of Comprehensive Income (Loss) Amount of Gain (Loss) Reclassified from AOCI Three Months Ended June 30, Total Amount of Line Item Presented Derivative Instrument 2020 2019 Location of amount reclassified 2020 2019 2020 2019 Foreign exchange contracts $ (3,279) $ 126 Net Sales $ 157,785 $ 238,263 $ 342 $ 2,096 Cost of Sales 85,856 107,073 (418) 138 Pre-tax gain (loss) $ (3,279) $ 126 $ (76) $ 2,234 Tax expense (benefit) (792) 30 (18) 540 Net gain (loss) $ (2,487) $ 96 $ (58) $ 1,694 Amount of Gain Recognized in AOCI Consolidated Condensed Statements of Comprehensive Income (Loss) Amount of Gain (Loss) Reclassified from AOCI Six Months Ended June 30, Total Amount of Line Item Presented Derivative Instrument 2020 2019 Location of amount reclassified 2020 2019 2020 2019 Foreign exchange contracts $ 1,015 $ 1,864 Net Sales $ 371,796 $ 456,641 $ 1,543 $ 3,593 Cost of Sales 180,707 204,013 (495) 239 Pre-tax gain $ 1,015 $ 1,864 $ 1,048 $ 3,832 Tax expense 245 450 254 926 Net gain $ 770 $ 1,414 $ 794 $ 2,906 At June 30, 2020, $0.9 million of net unrealized gains on forward contracts accounted for as cash flow hedges, and included in accumulated other comprehensive loss, are expected to be recognized in earnings in the next twelve months. Derivatives not designated as cash flow hedges Net gains and losses from derivative instruments not accounted for as hedges and gains and losses on our intercompany receivables on our consolidated condensed statements of comprehensive income (loss) were: Three Months Ended June 30, Six Months Ended June 30, Derivative Instrument Location on Consolidated Condensed Statements of Comprehensive Income (Loss) 2020 2019 2020 2019 Net loss on currency forward contracts Selling and administrative expense $ (302) $ (312) $ (547) $ (493) Net gain (loss) on currency transaction exposures Selling and administrative expense $ 22 $ 67 $ (169) $ (161) Balance sheet presentation We record these forward foreign exchange contracts at fair value. The following tables summarize the fair value for forward foreign exchange contracts outstanding at June 30, 2020 and December 31, 2019: June 30, 2020 Location on Consolidated Condensed Balance Sheet Asset Fair Value Liabilities Fair Value Net Derivatives designated as hedged instruments: Foreign exchange contracts Prepaids and other current assets $ 1,852 $ (1,738) $ 114 Foreign exchange contracts Other long-term liabilities 375 (919) (544) $ 2,227 $ (2,657) $ (430) Derivatives not designated as hedging instruments: Foreign exchange contracts Other current liabilities 27 (105) (78) Total derivatives $ 2,254 $ (2,762) $ (508) December 31, 2019 Location on Consolidated Condensed Balance Sheet Asset Fair Value Liabilities Fair Value Net Derivatives designated as hedged instruments: Foreign exchange contracts Prepaids and other current assets $ 2,307 $ (1,341) $ 966 Foreign exchange contracts Other long-term liabilities 38 (353) (315) $ 2,345 $ (1,694) $ 651 Derivatives not designated as hedging instruments: Foreign exchange contracts Other current liabilities 22 (159) (137) Total derivatives $ 2,367 $ (1,853) $ 514 Our forward foreign exchange contracts are subject to a master netting agreement and qualify for netting in the consolidated condensed balance sheets. Fair Value Disclosure. FASB guidance defines fair value and establishes a framework for measuring fair value and related disclosure requirements. This guidance applies when fair value measurements are required or permitted. The guidance indicates, among other things, that a fair value measurement assumes that the transaction to sell an asset or transfer a liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market for the asset or liability. Fair value is defined based upon an exit price model. Valuation Hierarchy. A valuation hierarchy was established for disclosure of the inputs to the valuations used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable for the asset or liability, including interest rates, yield curves and credit risks, or inputs that are derived principally from or corroborated by observable market data through correlation. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. There have been no significant changes in the assumptions. Valuation Techniques. Assets and liabilities carried at fair value and measured on a recurring basis as of June 30, 2020 consist of forward foreign exchange contracts. The Company values its forward foreign exchange contracts using quoted prices for similar assets. The most significant assumption is quoted currency rates. The value of the forward foreign exchange contract assets and liabilities were valued using Level 2 inputs and are listed in the table above.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2020
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consist of the following: June 30, December 31, Raw materials $ 58,428 $ 51,103 Work-in-process 16,507 15,142 Finished goods 100,780 98,371 Total $ 175,715 $ 164,616

Earnings (Loss) Per Share

Earnings (Loss) Per Share	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	Earnings (Loss) Per ShareBasic earnings (loss) per share (“basic EPS”) is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the reporting period. Diluted earnings (loss) per share (“diluted EPS”) gives effect to all dilutive potential shares outstanding resulting from employee stock options, restricted stock units, performance share units and stock appreciation rights ("SARs") during the period. The following table sets forth the computation of basic and diluted earnings (loss) per share for the three and six months ended June 30, 2020 and 2019: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Net income (loss) $ (27,400) $ 5,695 $ (21,473) $ 6,716 Basic – weighted average shares outstanding 28,542 28,276 28,506 28,228 Effect of dilutive potential securities — 1,061 — 969 Diluted – weighted average shares outstanding 28,542 29,337 28,506 29,197 Net income (loss) (per share) Basic $ (0.96) $ 0.20 $ (0.75) $ 0.24 Diluted (0.96) 0.19 (0.75) 0.23 The shares used in the calculation of diluted EPS exclude options and SARs to purchase shares where the exercise price was greater than the average market price of common shares for the period and the effect of the inclusion would be anti-dilutive. Such shares aggregated approximately 0.8 million and 0.6 million for the three and six months ended June 30, 2019, respectively. As the Company was in a net loss position for the three and six months ended June 30, 2020, there were no anti-dilutive shares. Our 2.625% convertible notes due in 2024 (the “Notes”) are convertible under certain circumstances, as defined in the indenture, into a combination of cash and CONMED common stock. The calculation of diluted EPS would include potential diluted shares upon conversion of the Notes when the average market price per share of our common stock for the period, is greater than the conversion price of the Notes of $88.80. We intend to settle in cash the principal outstanding and use the treasury stock method when calculating their potential dilutive effect, if any. We have entered into convertible notes hedge transactions to increase the effective conversion price of the Notes to $114.92. However, our convertible notes hedges are not included when calculating potential dilutive shares since their effect is always anti-dilutive.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	6 Months Ended
	Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets The changes in the net carrying amount of goodwill for the six months ended June 30, 2020 are as follows: Balance as of December 31, 2019 $ 618,042 Goodwill adjustment resulting from business acquisition (1,009) Foreign currency translation (348) Balance as of June 30, 2020 $ 616,685 Assets and liabilities of acquired businesses are recorded at their estimated fair values as of the date of acquisition. Goodwill represents costs in excess of fair values assigned to the underlying net assets of acquired businesses. During the six months ended June 30, 2020, the Company recorded a measurement period adjustment related to a prior business combination. Other intangible assets consist of the following: June 30, 2020 December 31, 2019 Weighted Average Amortization Period (Years) Gross Accumulated Gross Accumulated Intangible assets with definite lives: Customer and distributor relationships 24 $ 342,420 $ (124,865) $ 342,568 $ (115,311) Sales representation, marketing and promotional rights 25 149,376 (51,000) 149,376 (48,000) Patents and other intangible assets 15 72,209 (47,663) 70,646 (46,456) Developed technology 16 106,604 (16,438) 106,604 (13,171) Intangible assets with indefinite lives: Trademarks and tradenames 86,544 — 86,544 — 22 $ 757,153 $ (239,966) $ 755,738 $ (222,938) Customer and distributor relationships, trademarks and tradenames, developed technology and patents and other intangible assets primarily represent allocations of purchase price to identifiable intangible assets of acquired businesses. Sales representation, marketing and promotional rights represent intangible assets created under our agreement with Musculoskeletal Transplant Foundation (“MTF”). Amortization expense related to intangible assets which are subject to amortization totaled $8.5 million and $8.3 million in the three months ended June 30, 2020 and 2019, respectively, and $17.0 million and $15.7 million in the six months ended June 30, 2020 and 2019, respectively, and is included as a reduction of revenue (for amortization related to our sales representation, marketing and promotional rights) and in selling and administrative expense (for all other intangible assets) in the consolidated condensed statements of comprehensive income (loss). Included in developed technology is $6.0 million of earn-out consideration that is considered probable as of June 30, 2020 associated with a prior asset acquisition. This is recorded in other current liabilities at June 30, 2020. The estimated intangible asset amortization expense remaining for the year ending December 31, 2020 and for each of the five succeeding years is as follows: Amortization included in expense Amortization recorded as a reduction of revenue Total Remaining, 2020 $ 14,019 $ 3,000 $ 17,019 2021 27,449 6,000 33,449 2022 26,293 6,000 32,293 2023 25,516 6,000 31,516 2024 24,691 6,000 30,691 2025 24,947 6,000 30,947

Long Term Debt

Long Term Debt	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Long-term Debt	Long-Term Debt Long-term debt consists of the following: June 30, 2020 December 31, 2019 Revolving line of credit $ 258,000 $ 220,000 Term loan, net of deferred debt issuance costs of $1,697 and $1,528 in 2020 and 2019, respectively 246,740 253,535 2.625% convertible notes, net of deferred debt issuance costs of $6,363 and $7,252 in 2020 and 2019, respectively, and unamortized discount of $38,502 and $43,312 in 2020 and 2019, respectively 300,135 294,436 Financing leases 743 836 Total debt 805,618 768,807 Less: Current portion 15,193 13,596 Total long-term debt $ 790,425 $ 755,211 On February 7, 2019 we entered into a sixth amended and restated senior credit agreement consisting of: (a) a $265.0 million term loan facility and (b) a $585.0 million revolving credit facility. The revolving credit facility will terminate and the loans outstanding under the term loan facility will expire on the earlier of (i) February 7, 2024 or (ii) 91 days prior to the earliest scheduled maturity date of the 2.625% convertible notes due in 2024 described below, (if, as of such date, more than $150.0 million in aggregate principal amount of such convertible notes (or any refinancing thereof) remains outstanding). The term loan facility is payable in quarterly installments increasing over the term of the facility. Proceeds from the term loan facility and borrowings under the revolving credit facility were used to repay the then existing senior credit agreement and in part to finance the acquisition of Buffalo Filter. On April 17, 2020, we amended our sixth amended and restated senior credit agreement to suspend our required leverage ratios for up to four quarters as a result of the potential impact from the COVID-19 pandemic (as further described in Note 17). Under the terms of the amendment, there are certain minimum liquidity and fixed charge coverage ratio requirements. Interest rates are also adjusted so that the applicable margin for base rate loans is 2.50% per annum and for Eurocurrency rate loans is 3.50% per annum, and the applicable commitment fee rate for the revolving credit facility is 0.50%. Following the suspension period, the applicable margin will depend upon CONMED’s consolidated senior secured leverage ratio, using the pricing grid set forth in the amendment. Interest rates were at LIBOR (subject to 1.00% floor) plus an interest rate margin of 3.50% (4.50% at June 30, 2020). There were $248.4 million in borrowings outstanding on the term loan facility as of June 30, 2020. There were $258.0 million in borrowings outstanding under the revolving credit facility as of June 30, 2020. Our available borrowings on the revolving credit facility at June 30, 2020 were $324.5 million with approximately $2.5 million of the facility set aside for outstanding letters of credit. The sixth amended and restated senior credit agreement is collateralized by substantially all of our personal property and assets. The sixth amended and restated senior credit agreement contains covenants and restrictions which, among other things, require the maintenance of certain financial ratios and restrict dividend payments and the incurrence of certain indebtedness and other activities, including acquisitions and dispositions. We were in full compliance with these covenants and restrictions as of June 30, 2020. We are also required, under certain circumstances, to make mandatory prepayments from net cash proceeds from any issuance of equity and asset sales. On January 29, 2019, we issued $345.0 million in 2.625% convertible notes due in 2024 (the "Notes"). Interest is payable semi-annually in arrears on February 1 and August 1 of each year, commencing August 1, 2019. The Notes will mature on February 1, 2024, unless earlier repurchased or converted. The Notes represent subordinated unsecured obligations and are convertible under certain circumstances, as defined in the indenture, into a combination of cash and CONMED common stock. The Notes may be converted at an initial conversion rate of 11.2608 shares of our common stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $88.80 per share of common stock). Holders of the Notes may convert the Notes at their option at any time on or after November 1, 2023 through the second scheduled trading day preceding the maturity date. Holders of the Notes will also have the right to convert the Notes prior to November 1, 2023, but only upon the occurrence of specified events. The conversion rate is subject to anti-dilution adjustments if certain events occur. A portion of the net proceeds from the offering of the Notes were used as part of the financing for the Buffalo Filter acquisition and $21.0 million were used to pay the cost of certain convertible notes hedge transactions as further described below. Our effective borrowing rate for nonconvertible debt at the time of issuance of the Notes was estimated to be 6.14%, which resulted in $51.6 million of the $345.0 million aggregate principal amount of Notes issued, or $39.1 million after taxes, being attributable to equity. For the three months ended June 30, 2020 and 2019, we have recorded interest expense related to the amortization of debt discount on the Notes of $2.5 million and $2.3 million, respectively, and for the six months ended June 30, 2020 and 2019, we have recorded interest expense related to the amortization of debt discount on the Notes of $4.8 million and $3.8 million, respectively, at the effective interest rate of 6.14%. The debt discount on the Notes is being amortized through February 2024. For both the three months ended June 30, 2020 and 2019, we have recorded interest expense on the Notes of $2.3 million and for the six months ended June 30, 2020 and 2019, we have recorded interest expense on the Notes of $4.5 million and $3.8 million, respectively, at the contractual coupon rate of 2.625%. In connection with the offering of the Notes, we entered into convertible note hedge transactions with a number of financial institutions (each, an “option counterparty”). The convertible note hedge transactions cover, subject to anti-dilution adjustments substantially similar to those applicable to the Notes, the number of shares of our common stock underlying the Notes. Concurrently with entering into the convertible note hedge transactions, we also entered into separate warrant transactions with each option counterparty whereby we sold to such option counterparty warrants to purchase, subject to customary anti-dilution adjustments, the same number of shares of our common stock. The convertible note hedge transactions are expected generally to reduce the potential dilution upon conversion of the Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted Notes, as the case may be, in the event that the market price per share of our common stock, as measured under the terms of the convertible note hedge transactions, is greater than the strike price ($114.92) of the convertible note hedge transactions, which initially corresponds to the conversion price of the Notes and is subject to anti-dilution adjustments substantially similar to those applicable to the conversion rate of the Notes. If, however, the market price per share of our common stock, as measured under the terms of the warrant transactions, exceeds the strike price of the warrants, there would nevertheless be dilution to the extent that such market price exceeds the strike price of the warrants. The scheduled maturities of long-term debt outstanding at June 30, 2020 are as follows: Remaining 2020 $ 6,625 2021 18,219 2022 24,843 2023 456,750 2024 345,000

Guarantees

Guarantees	6 Months Ended
	Jun. 30, 2020
Guarantees [Abstract]
Guarantees	Guarantees We provide warranties on certain of our products at the time of sale and sell extended warranties. The standard warranty period for our capital equipment is generally one year and our extended warranties typically vary from one to three years. Liability under warranty policies is based upon a review of historical claim experience. Adjustments are made to accruals as claim data and historical experience warrant. Changes in the liability for standard warranties for the six months ended June 30, are as follows: 2020 2019 Balance as of January 1, $ 2,186 $ 1,585 Provision for warranties 427 1,020 Claims made (584) (483) Balance as of June 30, $ 2,029 $ 2,122 Costs associated with extended warranty repairs are recorded as incurred and amounted to $3.0 million and $2.8 million for the six months ended June 30, 2020 and 2019, respectively.

Pension Plan

Pension Plan	6 Months Ended
	Jun. 30, 2020
Retirement Benefits [Abstract]
Pension Plan	Pension Plan Net periodic pension cost consists of the following: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Service cost $ 179 $ 253 $ 358 $ 506 Interest cost on projected benefit obligation 639 782 1,278 1,564 Expected return on plan assets (1,255) (1,181) (2,510) (2,362) Net amortization and deferral 705 720 1,410 1,440 Net periodic pension cost $ 268 $ 574 $ 536 $ 1,148

Acquisition and Other Expense

Acquisition and Other Expense	6 Months Ended
	Jun. 30, 2020
Acquisition and Other Expense [Abstract]
Acquisition and Other Expense	Acquisition and Other Expense Acquisition and other expense consist of the following, which are included in cost of sales, selling and administrative expense or other expense depending on the nature of the charge: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Plant underutilization costs $ 6,586 $ — $ 6,586 $ — Product rationalization costs - inventory 2,169 — 2,169 — Restructuring costs 1,087 — 1,087 — Manufacturing consolidation costs 1,602 — 3,387 — Acquisition and integration costs 652 503 1,457 1,163 Acquisition and other expense included in cost of sales $ 12,096 $ 503 $ 14,686 $ 1,163 Restructuring costs $ 2,124 $ — $ 2,124 $ — Product rationalization costs - field inventory 2,095 — 2,095 — Acquisition and integration costs 439 2,461 1,192 9,706 Acquisition and other expense included in selling and administrative expense $ 4,658 $ 2,461 $ 5,411 $ 9,706 Debt refinancing costs included in other expense $ — $ — $ — $ 3,904 During the second quarter of 2020, we recorded a $6.6 million charge to cost of sales related to plant underutilization due to abnormally low production as a result of decreased sales caused by the COVID-19 pandemic. During the second quarter of 2020, we performed an analysis of our product lines and determined certain catalog numbers, principally related to capital equipment, would be discontinued and consolidated into existing product offerings. We consequently recorded a $2.2 million charge to cost of sales to write-off inventory of the discontinued products. In addition, we incurred $2.1 million in costs related to the write-off of field inventory used for customer demonstration and evaluation of the discontinued products which we charged to selling and administrative expense. During the second quarter of 2020, we incurred $1.1 million in restructuring costs related to a voluntary separation arrangement with employees as a result of the COVID-19 pandemic that were charged to cost of sales based on the job function of the affected employees. We additionally recorded a charge of $2.1 million primarily related to the restructuring of our Orthopedic sales force and a voluntary separation arrangement with employees as a result of the COVID-19 pandemic that was charged to selling and administrative expenses based on the nature of the costs and function of the affected employees. Of the $3.2 million in these restructuring costs, $2.0 million is included in accrued compensation and benefits within the consolidated condensed balance sheet at June 30, 2020. During the three and six months ended June 30, 2020, we incurred $1.6 million and $3.4 million, respectively, in costs related to the consolidation of certain manufacturing operations which were charged to cost of sales. These costs related to winding down operations at certain locations and moving production lines to other facilities. During the three and six months ended June 30, 2020, we recognized costs for inventory step-up adjustments and other costs related to a previous acquisition of $0.7 million and $1.5 million, respectively. During the three and six months ended June 30, 2019, we incurred costs of $0.5 million and $1.2 million, respectively, for inventory adjustments associated with the acquisition of Buffalo Filter as further described in Note 3. These costs were charged to cost of sales. During the three and six months ended June 30, 2020, we incurred $0.4 million and $1.2 million, respectively, in severance and integration costs mainly related to the Buffalo Filter acquisition. During the three and six months ended June 30, 2019, we incurred $2.5 million and $9.7 million, respectively, in costs associated with the acquisition of Buffalo Filter as further described in Note 3. These costs include investment banking fees in the first quarter of 2019, and, consulting fees, legal fees, severance and integration related costs in the three and six months ended June 30, 2019. These costs were included in selling and administrative expense. During the six months ended June 30, 2019, we incurred a $3.6 million charge related to commitment fees paid to certain of our lenders, which provided a financing commitment for the Buffalo Filter acquisition and recorded a loss on the early extinguishment of debt of $0.3 million in conjunction with the sixth amended and restated senior credit agreement.

Business Segment

Business Segment	6 Months Ended
	Jun. 30, 2020
Segment Reporting [Abstract]
Business Segment	Business Segment We are accounting and reporting for our business as a single operating segment entity engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. Our chief operating decision maker (the CEO) evaluates the various global product portfolios on a net sales basis and evaluates profitability, investment, cash flow metrics and allocates resources on a consolidated worldwide basis due to shared infrastructure and resources. Our product lines consist of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine instrumentation and small bone, large bone and specialty powered surgical instruments as well as imaging systems for use in minimally invasive surgery procedures including 2DHD and 3DHD vision technologies and fees related to the sales representation, promotion and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, a line of cardiac monitoring products as well as electrosurgical generators and related instruments. These product lines' net sales are as follows: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Orthopedic surgery $ 60,483 $ 115,757 $ 159,766 $ 229,194 General surgery 97,302 122,506 212,030 227,447 Consolidated net sales $ 157,785 $ 238,263 $ 371,796 $ 456,641

Legal Proceedings

Legal Proceedings	6 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	Legal Proceedings From time to time, the Company may receive an information request, subpoena or warrant from a government agency such as the Securities and Exchange Commission, Department of Justice, Equal Employment Opportunity Commission, the Occupational Safety and Health Administration, the United States Food and Drug Administration, the Department of Labor, the Treasury Department or other federal and state agencies or foreign governments or government agencies. These information requests, subpoenas or warrants may or may not be routine inquiries, or may begin as routine inquiries and over time develop into enforcement actions of various types. Likewise, if we receive reports of alleged misconduct from employees and third parties, we investigate as appropriate. Manufacturers of medical devices have been the subject of various enforcement actions relating to interactions with health care providers domestically or internationally whereby companies are claimed to have provided health care providers with inappropriate incentives to purchase their products. Similarly, the Foreign Corrupt Practices Act ("FCPA") imposes obligations on manufacturers with respect to interactions with health care providers who may be considered government officials based on their affiliation with public hospitals. The FCPA also requires publicly listed manufacturers to maintain accurate books and records, and maintain internal accounting controls sufficient to provide assurance that transactions are accurately recorded, lawful and in accordance with management's authorization. The FCPA poses unique challenges both because manufacturers operate in foreign cultures in which conduct illegal under the FCPA may not be illegal in local jurisdictions, and because, in some cases, a United States manufacturer may face risks under the FCPA based on the conduct of third parties over whom the manufacturer may not have complete control. While CONMED has not experienced any material enforcement action to date, there can be no assurance that the Company will not be subject to a material enforcement action in the future, or that the Company will not incur costs including, in the form of fees for lawyers and other consultants, that are material to the Company’s results of operations in the course of responding to a future inquiry or investigation. Manufacturers of medical products may face exposure to significant product liability claims, as well as patent infringement and other claims incurred in the ordinary course of business. To date, we have not experienced any claims that have been material to our financial statements or financial condition, but any such claims arising in the future could have a material adverse effect on our business, results of operations or cash flows. We currently maintain commercial product liability insurance of $30 million per incident and $30 million in the aggregate annually, which we believe is adequate. This coverage is on a claims-made basis. There can be no assurance that claims will not exceed insurance coverage, that the carriers will be solvent or that such insurance will be available to us in the future at a reasonable cost. Our operations are subject, and in the past have been subject, to a number of environmental laws and regulations governing, among other things, air emissions; wastewater discharges; the use, handling and disposal of hazardous substances and wastes; soil and groundwater remediation and employee health and safety. Likewise, the operations of our suppliers and sterilizers are subject to similar environmental laws and regulations. In some jurisdictions, environmental requirements may be expected to become more stringent in the future. In the United States, certain environmental laws can impose liability for the entire cost of site restoration upon each of the parties that may have contributed to conditions at the site regardless of fault or the lawfulness of the party’s activities. While we do not believe that the present costs of environmental compliance and remediation are material, there can be no assurance that future compliance or remedial obligations would not have a material adverse effect on our financial condition, results of operations or cash flows. In 2014, the Company acquired EndoDynamix, Inc. The agreement governing the terms of the acquisition provides that, if various conditions are met, certain contingent payments relating to the first commercial sale of the products (the milestone payment), as well as royalties based on sales (the revenue based payments), are due to the seller. In 2016, we notified the seller that there was a need to redesign the product, and that, as a consequence, the first commercial sale had been delayed. Consequently, the payment of contingent milestone and revenue-based payments were delayed. On January 18, 2017, the seller provided notice ("the Notice") seeking $12.7 million, which essentially represents the seller's view as to the sum of the projected contingent milestone and revenue-based payments on an accelerated basis. CONMED responded to the Notice denying that there was any basis for acceleration of the payments due under the acquisition agreement. On February 22, 2017, the representative of the former shareholders of EndoDynamix filed a complaint in Delaware Chancery Court claiming breach of contract with respect to the duty to commercialize the product and seeking the contingent payments on an accelerated basis. We believe that there was a substantive contractual basis to support the Company's decision to redesign the product, such that there was no legitimate basis for seeking the acceleration of the contingent payments at that time. In the third quarter of 2018, the Company decided to halt the development of the EndoDynamix clip applier. We previously recorded a charge to write off assets and released a previously accrued contingent consideration liability. A non-jury trial is now scheduled to take place in December 2020. We expect to defend the claims asserted by the sellers of EndoDynamix in the Delaware Court, although there can be no assurance that we will prevail in the litigation. On June 17, 2020, our Seoul, South Korea Office was served with a search warrant by the Incheon Customs Office ("ICO") as part of what we believe to be an industry-wide criminal investigation concerning alleged manipulation of transfer pricing and maximum reimbursement pricing. We understand that the period under investigation with respect to CONMED currently relates to 2016-2019, although this could change as the investigation develops over time. CONMED is cooperating with the investigation, which we believe is in its early stages. The ICO has previously audited the transfer pricing applied to the majority of our imports into Korea, without any resulting material adjustments. We believe our transfer pricing was appropriate, on an aggregate basis, and we intend to vigorously defend our position in the investigation, although there can be no assurance with respect to the outcome of the investigation, or the related costs, given that the investigation is in a relatively early stage. We record reserves sufficient to cover probable and estimable losses associated with any such pending claims. We do not expect that the resolution of any pending claims, investigations or reports of alleged misconduct will have a material adverse effect on our financial condition, results of operations or cash flows. There can be no assurance, however, that future claims or investigations, or the costs associated with responding to such claims, investigations or reports of misconduct, especially claims and investigations not covered by insurance, will not have a material adverse effect on our financial condition, results of operations or cash flows.

New Accounting Pronouncements

New Accounting Pronouncements	6 Months Ended
	Jun. 30, 2020
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements Recently Adopted Accounting Standards In June 2016, the FASB issued ASU No. 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, along with subsequent amendments issued in 2019. This ASU requires instruments measured at amortized cost, including accounts receivable, to be presented at the net amount expected to be collected. The new model requires an entity to estimate credit losses based on historical information, current information, and reasonable and supportable forecasts, including estimates of prepayments. This ASU is effective for fiscal years beginning after December 31, 2019 and the Company adopted the new standard on January 1, 2020. We adopted this ASU by applying historical loss rates to our accounts receivable aging schedule to estimate expected credit losses. We further adjusted expected credit losses for specifically identified and forecasted credit losses. This update did not have a material impact on our net income (loss), earnings (loss) per share or cash flows. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement, which modifies the disclosure requirements on fair value measurements. This ASU is effective for fiscal years beginning after December 15, 2019 and early adoption is permitted. We adopted this update as of January 1, 2020 and it did not have a material impact on our net income (loss), earnings (loss) per share or cash flows. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which results in the removal of certain exceptions to the general principles of ASC 740 and simplifies other aspects of the accounting for income taxes. This ASU is effective for fiscal years beginning after December 15, 2020 and early adoption is permitted in any interim period. We early adopted this new guidance effective April 1, 2020 and it did not have a material impact on the consolidated financial statements. Recently Issued Accounting Standards, Not Yet Adopted In August 2018, the FASB issued ASU 2018-14, Compensation-Retirement Benefits-Defined Benefit Plans-General (Topic 715-20): Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans, which modifies the disclosure requirements for defined benefit pension plans and other postretirement plans. This ASU is effective for fiscal years beginning after December 15, 2020 and early adoption is permitted. The Company is currently assessing the impact of this guidance on our consolidated financial statements.

COVID-19

COVID-19	6 Months Ended
	Jun. 30, 2020
COVID-19 [Abstract]
COVID-19	COVID-19 We experienced lower sales for the three and six months ended June 30, 2020 as a result of the emergence of the COVID-19 virus, which was first identified in Wuhan, China in December 2019 and then spread throughout Asia before emerging and becoming a pandemic in the United States, Europe and elsewhere. Our sales were negatively impacted first in the Asia Pacific geography and later in the United States, Europe and elsewhere as lockdown measures were implemented and hospitals and surgery centers postponed many non-urgent surgical procedures in order to minimize the risk of infection with COVID-19. We believe the deferral of non-urgent procedures has had a greater impact on our Orthopedic product lines compared to General Surgery as a result of the nature of the products and the procedures in which they are used. In compliance with various governmental orders, beginning in March we restricted access to our main facilities to only essential personnel required to be onsite (primarily manufacturing and distribution) with substantially all other personnel working remotely. As a medical device manufacturer, we were designated as an “essential business” by the relevant authorities in New York, Florida, Georgia and Mexico and have maintained production or distribution at our facilities in these locations. We expect to continue to experience materially lower sales for as long as interruptions to business and economic activities, and deferral of surgeries continues. We anticipate this will materially impact the results of operations for at least the remainder of 2020. As a result, on April 17, 2020, we amended our sixth amended and restated senior credit agreement to suspend our required leverage ratios for up to four quarters. Under the terms of the amendment, we have certain minimum liquidity and fixed charge coverage ratio requirements with which we were in full compliance as of June 30, 2020. We are forecasting that sales and earnings will be sufficient to remain in compliance with the liquidity and fixed charge coverage ratio requirements under the terms of the amendment and we will have sufficient availability under our revolving credit facility to meet our liquidity needs. We have undertaken steps to reduce our spending and expenses in light of our expectation that our revenues will be depressed for at least the remainder of 2020. While we expect that we will be well positioned when surgeries begin to return to their pre-pandemic levels, we are unable to predict with certainty how long the COVID-19 pandemic will last, or resurgence thereof, or how severe its economic impact will be. Even after the COVID-19 pandemic and government responses thereto have subsided, residual economic and other effects may have an impact on the demand for post-pandemic surgery levels that are difficult to predict. If the downturn is more severe and prolonged than we currently expect, we may need to take further steps to reduce our costs, or to refinance our debt.

New Accounting Pronouncements (

New Accounting Pronouncements (Policies)	6 Months Ended
	Jun. 30, 2020
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements Recently Adopted Accounting Standards In June 2016, the FASB issued ASU No. 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, along with subsequent amendments issued in 2019. This ASU requires instruments measured at amortized cost, including accounts receivable, to be presented at the net amount expected to be collected. The new model requires an entity to estimate credit losses based on historical information, current information, and reasonable and supportable forecasts, including estimates of prepayments. This ASU is effective for fiscal years beginning after December 31, 2019 and the Company adopted the new standard on January 1, 2020. We adopted this ASU by applying historical loss rates to our accounts receivable aging schedule to estimate expected credit losses. We further adjusted expected credit losses for specifically identified and forecasted credit losses. This update did not have a material impact on our net income (loss), earnings (loss) per share or cash flows. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement, which modifies the disclosure requirements on fair value measurements. This ASU is effective for fiscal years beginning after December 15, 2019 and early adoption is permitted. We adopted this update as of January 1, 2020 and it did not have a material impact on our net income (loss), earnings (loss) per share or cash flows. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which results in the removal of certain exceptions to the general principles of ASC 740 and simplifies other aspects of the accounting for income taxes. This ASU is effective for fiscal years beginning after December 15, 2020 and early adoption is permitted in any interim period. We early adopted this new guidance effective April 1, 2020 and it did not have a material impact on the consolidated financial statements. Recently Issued Accounting Standards, Not Yet Adopted In August 2018, the FASB issued ASU 2018-14, Compensation-Retirement Benefits-Defined Benefit Plans-General (Topic 715-20): Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans, which modifies the disclosure requirements for defined benefit pension plans and other postretirement plans. This ASU is effective for fiscal years beginning after December 15, 2020 and early adoption is permitted. The Company is currently assessing the impact of this guidance on our consolidated financial statements.

Business Acquisition (Tables)

Business Acquisition (Tables)	6 Months Ended
	Jun. 30, 2020
Business Combinations [Abstract]
Business Acquisition, Pro Forma Information	The unaudited pro forma information for the three and six months ended June 30, 2019, assuming the Buffalo Filter Acquisition occurred as of January 1, 2018 are presented below. This information has been prepared for comparative purposes only and does not purport to be indicative of the results of operations which actually would have resulted had the Buffalo Filter Acquisition occurred on the dates indicated, or which may result in the future. Three Months Ended June 30, Six Months Ended June 30, 2019 2019 Net sales $ 238,263 $ 461,660 Net income 8,625 17,370

Revenues (Tables)

Revenues (Tables)	6 Months Ended
	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following tables present revenue disaggregated by primary geographic market where the products are sold, by product line and timing of revenue recognition: Three Months Ended Three Months Ended June 30, 2020 June 30, 2019 Orthopedic Surgery General Surgery Total Orthopedic Surgery General Surgery Total Primary Geographic Markets United States $ 21,387 $ 66,038 $ 87,425 $ 43,335 $ 85,601 $ 128,936 Americas (excluding the United States) 5,582 4,637 10,219 15,781 7,823 23,604 Europe, Middle East & Africa 13,715 16,146 29,861 31,099 15,763 46,862 Asia Pacific 19,799 10,481 30,280 25,542 13,319 38,861 Total sales from contracts with customers $ 60,483 $ 97,302 $ 157,785 $ 115,757 $ 122,506 $ 238,263 Timing of Revenue Recognition Goods transferred at a point in time $ 53,670 $ 96,422 $ 150,092 $ 106,772 $ 121,927 $ 228,699 Services transferred over time 6,813 880 7,693 8,985 579 9,564 Total sales from contracts with customers $ 60,483 $ 97,302 $ 157,785 $ 115,757 $ 122,506 $ 238,263 Six Months Ended Six Months Ended June 30, 2020 June 30, 2019 Orthopedic Surgery General Surgery Total Orthopedic Surgery General Surgery Total Primary Geographic Markets United States $ 58,426 $ 147,847 $ 206,273 $ 88,590 $ 157,371 $ 245,961 Americas (excluding the United States) 21,385 12,617 34,002 30,823 15,286 46,109 Europe, Middle East & Africa 39,622 32,761 72,383 61,505 31,688 93,193 Asia Pacific 40,333 18,805 59,138 48,276 23,102 71,378 Total sales from contracts with customers $ 159,766 $ 212,030 $ 371,796 $ 229,194 $ 227,447 $ 456,641 Timing of Revenue Recognition Goods transferred at a point in time $ 144,222 $ 210,324 $ 354,546 $ 211,511 $ 226,351 $ 437,862 Services transferred over time 15,544 1,706 17,250 17,683 1,096 18,779 Total sales from contracts with customers $ 159,766 $ 212,030 $ 371,796 $ 229,194 $ 227,447 $ 456,641
Contract with Customer, Asset and Liability	Contract liability balances related to the sale of extended warranties to customers are as follows: June 30, 2020 December 31, 2019 Contract liability $ 13,251 $ 14,276

Comprehensive Income (Loss) (Ta

Comprehensive Income (Loss) (Tables)	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Schedule of Comprehensive Income (Loss)	Comprehensive income (loss) consists of the following: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Net income (loss) $ (27,400) $ 5,695 $ (21,473) $ 6,716 Other comprehensive income (loss): Pension liability, net of income tax (income tax expense of $170 and $174 for the three months ended June 30, 2020 and 2019, respectively, and $340 and $347 for the six months ended June 30, 2020 and 2019, respectively) 535 546 1,070 1,093 Cash flow hedging loss, net of income tax (income tax benefit of $774 and $509 for the three months ended June 30, 2020 and 2019, respectively, and $8 and $475 for the six months ended June 30, 2020 and 2019, respectively) (2,429) (1,598) (24) (1,492) Foreign currency translation adjustment 4,581 1,108 (5,407) 530 Comprehensive income (loss) $ (24,713) $ 5,751 $ (25,834) $ 6,847
Schedule of Accumulated Other Comprehensive Loss	Accumulated other comprehensive loss consists of the following: Cash Flow Pension Cumulative Accumulated Balance, December 31, 2019 $ 493 $ (31,691) $ (28,079) $ (59,277) Other comprehensive income (loss) before reclassifications, net of tax 770 — (5,407) (4,637) Amounts reclassified from accumulated other comprehensive income (loss) before tax a (1,048) 1,410 — 362 Income tax 254 (340) — (86) Net current-period other comprehensive income (loss) (24) 1,070 (5,407) (4,361) Balance, June 30, 2020 $ 469 $ (30,621) $ (33,486) $ (63,638) Cash Flow Pension Cumulative Accumulated Balance, December 31, 2018 $ 4,085 $ (31,718) $ (28,104) $ (55,737) Other comprehensive income (loss) before reclassifications, net of tax 1,414 — 530 1,944 Amounts reclassified from accumulated other comprehensive income (loss) before tax a (3,832) 1,440 — (2,392) Income tax 926 (347) — 579 Net current-period other comprehensive income (loss) (1,492) 1,093 530 131 Balance, June 30, 2019 $ 2,593 $ (30,625) $ (27,574) $ (55,606) (a) The cash flow hedging gain (loss) and pension liability accumulated other comprehensive income (loss) components are included in sales or cost of sales and as a component of net periodic pension cost, respectively. Refer to Note 6 and Note 12, respectively, for further details.

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Schedule of Notional Amounts of Outstanding Derivative Positions	The following table presents the notional contract amounts for forward contracts outstanding: As of FASB ASC Topic 815 Designation June 30, 2020 December 31, 2019 Forward exchange contracts Cash flow hedge $ 122,556 $ 156,818 Forward exchange contracts Non-designated 37,901 33,867
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)	Foreign exchange contracts designated as cash flow hedges had the following effects on accumulated other comprehensive income (loss) and net earnings on our consolidated condensed statements of comprehensive income (loss) and our consolidated condensed balance sheets: Amount of Gain (Loss) Recognized in AOCI Consolidated Condensed Statements of Comprehensive Income (Loss) Amount of Gain (Loss) Reclassified from AOCI Three Months Ended June 30, Total Amount of Line Item Presented Derivative Instrument 2020 2019 Location of amount reclassified 2020 2019 2020 2019 Foreign exchange contracts $ (3,279) $ 126 Net Sales $ 157,785 $ 238,263 $ 342 $ 2,096 Cost of Sales 85,856 107,073 (418) 138 Pre-tax gain (loss) $ (3,279) $ 126 $ (76) $ 2,234 Tax expense (benefit) (792) 30 (18) 540 Net gain (loss) $ (2,487) $ 96 $ (58) $ 1,694 Amount of Gain Recognized in AOCI Consolidated Condensed Statements of Comprehensive Income (Loss) Amount of Gain (Loss) Reclassified from AOCI Six Months Ended June 30, Total Amount of Line Item Presented Derivative Instrument 2020 2019 Location of amount reclassified 2020 2019 2020 2019 Foreign exchange contracts $ 1,015 $ 1,864 Net Sales $ 371,796 $ 456,641 $ 1,543 $ 3,593 Cost of Sales 180,707 204,013 (495) 239 Pre-tax gain $ 1,015 $ 1,864 $ 1,048 $ 3,832 Tax expense 245 450 254 926 Net gain $ 770 $ 1,414 $ 794 $ 2,906
Derivatives Not Designated as Hedging Instruments	Net gains and losses from derivative instruments not accounted for as hedges and gains and losses on our intercompany receivables on our consolidated condensed statements of comprehensive income (loss) were: Three Months Ended June 30, Six Months Ended June 30, Derivative Instrument Location on Consolidated Condensed Statements of Comprehensive Income (Loss) 2020 2019 2020 2019 Net loss on currency forward contracts Selling and administrative expense $ (302) $ (312) $ (547) $ (493) Net gain (loss) on currency transaction exposures Selling and administrative expense $ 22 $ 67 $ (169) $ (161)
Schedule of Fair Value for Forward Foreign Exchange Contracts	The following tables summarize the fair value for forward foreign exchange contracts outstanding at June 30, 2020 and December 31, 2019: June 30, 2020 Location on Consolidated Condensed Balance Sheet Asset Fair Value Liabilities Fair Value Net Derivatives designated as hedged instruments: Foreign exchange contracts Prepaids and other current assets $ 1,852 $ (1,738) $ 114 Foreign exchange contracts Other long-term liabilities 375 (919) (544) $ 2,227 $ (2,657) $ (430) Derivatives not designated as hedging instruments: Foreign exchange contracts Other current liabilities 27 (105) (78) Total derivatives $ 2,254 $ (2,762) $ (508) December 31, 2019 Location on Consolidated Condensed Balance Sheet Asset Fair Value Liabilities Fair Value Net Derivatives designated as hedged instruments: Foreign exchange contracts Prepaids and other current assets $ 2,307 $ (1,341) $ 966 Foreign exchange contracts Other long-term liabilities 38 (353) (315) $ 2,345 $ (1,694) $ 651 Derivatives not designated as hedging instruments: Foreign exchange contracts Other current liabilities 22 (159) (137) Total derivatives $ 2,367 $ (1,853) $ 514

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2020
Inventory Disclosure [Abstract]
Schedule of inventory	Inventories consist of the following: June 30, December 31, Raw materials $ 58,428 $ 51,103 Work-in-process 16,507 15,142 Finished goods 100,780 98,371 Total $ 175,715 $ 164,616

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Schedule of calculation of basic and diluted earnings (loss) per share	The following table sets forth the computation of basic and diluted earnings (loss) per share for the three and six months ended June 30, 2020 and 2019: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Net income (loss) $ (27,400) $ 5,695 $ (21,473) $ 6,716 Basic – weighted average shares outstanding 28,542 28,276 28,506 28,228 Effect of dilutive potential securities — 1,061 — 969 Diluted – weighted average shares outstanding 28,542 29,337 28,506 29,197 Net income (loss) (per share) Basic $ (0.96) $ 0.20 $ (0.75) $ 0.24 Diluted (0.96) 0.19 (0.75) 0.23

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The changes in the net carrying amount of goodwill for the six months ended June 30, 2020 are as follows: Balance as of December 31, 2019 $ 618,042 Goodwill adjustment resulting from business acquisition (1,009) Foreign currency translation (348) Balance as of June 30, 2020 $ 616,685
Schedule of Finite-Lived and Indefinite-Lived Intangible Assets	Other intangible assets consist of the following: June 30, 2020 December 31, 2019 Weighted Average Amortization Period (Years) Gross Accumulated Gross Accumulated Intangible assets with definite lives: Customer and distributor relationships 24 $ 342,420 $ (124,865) $ 342,568 $ (115,311) Sales representation, marketing and promotional rights 25 149,376 (51,000) 149,376 (48,000) Patents and other intangible assets 15 72,209 (47,663) 70,646 (46,456) Developed technology 16 106,604 (16,438) 106,604 (13,171) Intangible assets with indefinite lives: Trademarks and tradenames 86,544 — 86,544 — 22 $ 757,153 $ (239,966) $ 755,738 $ (222,938)
Schedule of Estimated Amortization Expense	The estimated intangible asset amortization expense remaining for the year ending December 31, 2020 and for each of the five succeeding years is as follows: Amortization included in expense Amortization recorded as a reduction of revenue Total Remaining, 2020 $ 14,019 $ 3,000 $ 17,019 2021 27,449 6,000 33,449 2022 26,293 6,000 32,293 2023 25,516 6,000 31,516 2024 24,691 6,000 30,691 2025 24,947 6,000 30,947

Long Term Debt (Tables)

Long Term Debt (Tables)	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Schedule of Long-term Debt	Long-term debt consists of the following: June 30, 2020 December 31, 2019 Revolving line of credit $ 258,000 $ 220,000 Term loan, net of deferred debt issuance costs of $1,697 and $1,528 in 2020 and 2019, respectively 246,740 253,535 2.625% convertible notes, net of deferred debt issuance costs of $6,363 and $7,252 in 2020 and 2019, respectively, and unamortized discount of $38,502 and $43,312 in 2020 and 2019, respectively 300,135 294,436 Financing leases 743 836 Total debt 805,618 768,807 Less: Current portion 15,193 13,596 Total long-term debt $ 790,425 $ 755,211
Schedule of Maturities of Long-term Debt	The scheduled maturities of long-term debt outstanding at June 30, 2020 are as follows: Remaining 2020 $ 6,625 2021 18,219 2022 24,843 2023 456,750 2024 345,000

Guarantees (Tables)

Guarantees (Tables)	6 Months Ended
	Jun. 30, 2020
Guarantees [Abstract]
Changes in the carrying amount of service and product warranties	Changes in the liability for standard warranties for the six months ended June 30, are as follows: 2020 2019 Balance as of January 1, $ 2,186 $ 1,585 Provision for warranties 427 1,020 Claims made (584) (483) Balance as of June 30, $ 2,029 $ 2,122

Pension Plan (Tables)

Pension Plan (Tables)	6 Months Ended
	Jun. 30, 2020
Retirement Benefits [Abstract]
Schedule of net benefit cost	Net periodic pension cost consists of the following: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Service cost $ 179 $ 253 $ 358 $ 506 Interest cost on projected benefit obligation 639 782 1,278 1,564 Expected return on plan assets (1,255) (1,181) (2,510) (2,362) Net amortization and deferral 705 720 1,410 1,440 Net periodic pension cost $ 268 $ 574 $ 536 $ 1,148

Acquisition and Other Expense (

Acquisition and Other Expense (Tables)	6 Months Ended
	Jun. 30, 2020
Acquisition and Other Expense [Abstract]
Schedule of Acquisition and Other Operating Expense	Acquisition and other expense consist of the following, which are included in cost of sales, selling and administrative expense or other expense depending on the nature of the charge: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Plant underutilization costs $ 6,586 $ — $ 6,586 $ — Product rationalization costs - inventory 2,169 — 2,169 — Restructuring costs 1,087 — 1,087 — Manufacturing consolidation costs 1,602 — 3,387 — Acquisition and integration costs 652 503 1,457 1,163 Acquisition and other expense included in cost of sales $ 12,096 $ 503 $ 14,686 $ 1,163 Restructuring costs $ 2,124 $ — $ 2,124 $ — Product rationalization costs - field inventory 2,095 — 2,095 — Acquisition and integration costs 439 2,461 1,192 9,706 Acquisition and other expense included in selling and administrative expense $ 4,658 $ 2,461 $ 5,411 $ 9,706 Debt refinancing costs included in other expense $ — $ — $ — $ 3,904

Business Segment (Tables)

Business Segment (Tables)	6 Months Ended
	Jun. 30, 2020
Segment Reporting [Abstract]
Schedule of net sales information by product line	These product lines' net sales are as follows: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Orthopedic surgery $ 60,483 $ 115,757 $ 159,766 $ 229,194 General surgery 97,302 122,506 212,030 227,447 Consolidated net sales $ 157,785 $ 238,263 $ 371,796 $ 456,641

Business Acquisition (Details)

Business Acquisition (Details) - USD ($) $ in Thousands	Feb. 11, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Business Acquisition [Line Items]
Net sales			$ 238,263		$ 461,660
Net income			8,625		17,370
Net sales		$ 157,785	238,263	$ 371,796	456,641
Payments to acquire businesses, gross	$ 365,000			$ 3,800
Buffalo Filter LLC
Business Acquisition [Line Items]
Net sales			13,500		19,500
Pro Forma | Acquisition-related Costs | Cost of Sales
Business Acquisition [Line Items]
Business acquisition costs			500		1,200
Pro Forma | Acquisition-related Costs | Selling and Administrative Expenses
Business Acquisition [Line Items]
Business acquisition costs			$ 2,500		$ 9,700

Revenues (Disaggregated Revenue

Revenues (Disaggregated Revenues) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Disaggregation of Revenue [Line Items]
Net Sales	$ 157,785	$ 238,263	$ 371,796	$ 456,641
Goods transferred at a point in time
Disaggregation of Revenue [Line Items]
Net Sales	150,092	228,699	354,546	437,862
Services transferred over time
Disaggregation of Revenue [Line Items]
Net Sales	7,693	9,564	17,250	18,779
Orthopedic Surgery
Disaggregation of Revenue [Line Items]
Net Sales	60,483	115,757	159,766	229,194
Orthopedic Surgery | Goods transferred at a point in time
Disaggregation of Revenue [Line Items]
Net Sales	53,670	106,772	144,222	211,511
Orthopedic Surgery | Services transferred over time
Disaggregation of Revenue [Line Items]
Net Sales	6,813	8,985	15,544	17,683
General Surgery
Disaggregation of Revenue [Line Items]
Net Sales	97,302	122,506	212,030	227,447
General Surgery | Goods transferred at a point in time
Disaggregation of Revenue [Line Items]
Net Sales	96,422	121,927	210,324	226,351
General Surgery | Services transferred over time
Disaggregation of Revenue [Line Items]
Net Sales	880	579	1,706	1,096
United States
Disaggregation of Revenue [Line Items]
Net Sales	87,425	128,936	206,273	245,961
United States | Orthopedic Surgery
Disaggregation of Revenue [Line Items]
Net Sales	21,387	43,335	58,426	88,590
United States | General Surgery
Disaggregation of Revenue [Line Items]
Net Sales	66,038	85,601	147,847	157,371
Americas (excluding the United States)
Disaggregation of Revenue [Line Items]
Net Sales	10,219	23,604	34,002	46,109
Americas (excluding the United States) | Orthopedic Surgery
Disaggregation of Revenue [Line Items]
Net Sales	5,582	15,781	21,385	30,823
Americas (excluding the United States) | General Surgery
Disaggregation of Revenue [Line Items]
Net Sales	4,637	7,823	12,617	15,286
Europe, Middle East & Africa
Disaggregation of Revenue [Line Items]
Net Sales	29,861	46,862	72,383	93,193
Europe, Middle East & Africa | Orthopedic Surgery
Disaggregation of Revenue [Line Items]
Net Sales	13,715	31,099	39,622	61,505
Europe, Middle East & Africa | General Surgery
Disaggregation of Revenue [Line Items]
Net Sales	16,146	15,763	32,761	31,688
Asia Pacific
Disaggregation of Revenue [Line Items]
Net Sales	30,280	38,861	59,138	71,378
Asia Pacific | Orthopedic Surgery
Disaggregation of Revenue [Line Items]
Net Sales	19,799	25,542	40,333	48,276
Asia Pacific | General Surgery
Disaggregation of Revenue [Line Items]
Net Sales	$ 10,481	$ 13,319	$ 18,805	$ 23,102

Revenues (Customer Liability) (

Revenues (Customer Liability) (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
Contract liability	$ 13,251		$ 14,276
Revenue recognized	$ 5,500	$ 4,000

Comprehensive Income (Loss) (De

Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
Equity [Abstract]
Net income (loss)	$ (27,400)		$ 5,695		$ (21,473)	$ 6,716
Pension liability, net of income tax	535		546		1,070	1,093
Cash flow hedging gain (loss), net of income tax	(2,429)		(1,598)		(24)	(1,492)
Foreign currency translation adjustments	4,581		1,108		(5,407)	530
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	(24,713)	$ (1,121)	5,751	$ 1,096	(25,834)	6,847
Pension liability, tax	170		174		340	347
Cash flow hedging gain (loss), tax	$ (774)		$ (509)		$ (8)	$ (475)

Comprehensive Income (Loss) (Ac

Comprehensive Income (Loss) (Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($) $ in Thousands		6 Months Ended
		Jun. 30, 2020	Jun. 30, 2019
Accumulated other comprehensive income (loss) [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Net of Tax		$ (59,277)
Accumulated Other Comprehensive Income (Loss), Net of Tax		(63,638)
Accumulated Other Comprehensive Loss
Accumulated other comprehensive income (loss) [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Net of Tax		(59,277)	$ (55,737)
Other comprehensive income (loss) before reclassifications, net of tax		(4,637)	1,944
Amounts reclassified from other accumulated comprehensive income (loss) before tax	[1]	362	(2,392)
Reclassification from AOCI, Current Period, Tax		(86)	579
Net current-period other comprehensive income (loss)		(4,361)	131
Accumulated Other Comprehensive Income (Loss), Net of Tax		(63,638)	(55,606)
Cash Flow Hedging Gain (Loss)
Accumulated other comprehensive income (loss) [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Net of Tax		493	4,085
Other comprehensive income (loss) before reclassifications, net of tax		770	1,414
Amounts reclassified from other accumulated comprehensive income (loss) before tax	[1]	(1,048)	(3,832)
Reclassification from AOCI, Current Period, Tax		254	926
Net current-period other comprehensive income (loss)		(24)	(1,492)
Accumulated Other Comprehensive Income (Loss), Net of Tax		469	2,593
Pension Liability
Accumulated other comprehensive income (loss) [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Net of Tax		(31,691)	(31,718)
Other comprehensive income (loss) before reclassifications, net of tax		0	0
Amounts reclassified from other accumulated comprehensive income (loss) before tax	[1]	1,410	1,440
Reclassification from AOCI, Current Period, Tax		(340)	(347)
Net current-period other comprehensive income (loss)		1,070	1,093
Accumulated Other Comprehensive Income (Loss), Net of Tax		(30,621)	(30,625)
Cumulative Translation Adjustments
Accumulated other comprehensive income (loss) [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Net of Tax		(28,079)	(28,104)
Other comprehensive income (loss) before reclassifications, net of tax		(5,407)	530
Amounts reclassified from other accumulated comprehensive income (loss) before tax	[1]	0	0
Reclassification from AOCI, Current Period, Tax		0	0
Net current-period other comprehensive income (loss)		(5,407)	530
Accumulated Other Comprehensive Income (Loss), Net of Tax		$ (33,486)	$ (27,574)
[1]	The cash flow hedging gain (loss) and pension liability accumulated other comprehensive income (loss) components are included in sales or cost of sales and as a component of net periodic pension cost, respectively. Refer to Note 6 and Note 12, respectively, for further details.

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Amounts Recorded In and Reclassified From AOCI) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Net sales	$ 157,785	$ 238,263	$ 371,796	$ 456,641
Cost of sales	85,856	107,073	180,707	204,013
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax	(3,279)	126	1,015	1,864
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax	(792)	30	245	450
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax	(2,487)	96	770	1,414
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax	(76)	2,234	1,048	3,832
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax	(18)	540	254	926
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax	(58)	1,694	794	2,906
Revenues
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax	342	2,096	1,543	3,593
Cost of Sales
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax	$ (418)	$ 138	$ (495)	$ 239

Fair Value of Financial Instr_4

Fair Value of Financial Instruments (Foreign Currency Forward Contracts) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Derivative [Line Items]
Foreign Currency Transaction Gain (Loss), before Tax	$ 22	$ 67	$ (169)	$ (161)
Derivative Assets and Liabilities at Fair Value [Abstract]
Asset Fair Value	2,254		2,254		$ 2,367
Liabilities Fair Value	(2,762)		(2,762)		(1,853)
Net Fair Value	(508)		(508)		514
Foreign Currency Forward Contracts
Derivative [Line Items]
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments	(302)	$ (312)	(547)	$ (493)
Derivatives designated as hedged instruments: | Foreign Currency Forward Contracts
Derivative Assets and Liabilities at Fair Value [Abstract]
Asset Fair Value	2,227		2,227		2,345
Liabilities Fair Value	(2,657)		(2,657)		(1,694)
Net Fair Value	(430)		(430)		651
Derivatives designated as hedged instruments: | Foreign Currency Forward Contracts | Prepaids and other current assets
Derivative Assets and Liabilities at Fair Value [Abstract]
Asset Fair Value	1,852		1,852		2,307
Liabilities Fair Value	(1,738)		(1,738)		(1,341)
Net Fair Value	114		114		966
Derivatives designated as hedged instruments: | Foreign Currency Forward Contracts | Other Noncurrent Liabilities [Member]
Derivative Assets and Liabilities at Fair Value [Abstract]
Asset Fair Value	375		375		38
Liabilities Fair Value	(919)		(919)		(353)
Net Fair Value	(544)		(544)		(315)
Derivatives not designated as hedging instruments: | Foreign Currency Forward Contracts
Derivative [Line Items]
Notional amount of cash flow hedges	37,901		37,901		33,867
Derivatives not designated as hedging instruments: | Foreign Currency Forward Contracts | Other Current Liabilities [Member]
Derivative Assets and Liabilities at Fair Value [Abstract]
Asset Fair Value	27		27		22
Liabilities Fair Value	(105)		(105)		(159)
Net Fair Value	(78)		$ (78)		(137)
Cash flow hedge | Foreign Currency Forward Contracts
Derivative [Line Items]
Maximum Length of Time Hedged in Cash Flow Hedge			2 years
Notional amount of cash flow hedges	122,556		$ 122,556		$ 156,818
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months	$ 900		$ 900
Derivatives not designated as hedging instruments: | Foreign Currency Forward Contracts
Derivative [Line Items]
Maximum Length of Time Hedged in Cash Flow Hedge			1 month

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 58,428	$ 51,103
Work-in-process	16,507	15,142
Finished goods	100,780	98,371
Total inventory	$ 175,715	$ 164,616

Earnings (Loss) Per Share (Deta

Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Earnings Per Share [Abstract]
Net income (loss)	$ (27,400)	$ 5,695	$ (21,473)	$ 6,716
Basic-weighted average shares outstanding (in shares)	28,542	28,276	28,506	28,228
Effect of dilutive potential securities (in shares)	0	1,061	0	969
Diluted- weighted average shares outstanding (in shares)	28,542	29,337	28,506	29,197
Basic (in dollars per share)	$ (0.96)	$ 0.20	$ (0.75)	$ 0.24
Diluted (in dollars per share)	$ (0.96)	$ 0.19	$ (0.75)	$ 0.23
Antidilutive securities excluded from computation of earnings per share (in shares)		800		600

Earnings (Loss) Per Share - Con

Earnings (Loss) Per Share - Convertible Notes (Details) - Convertible Notes Payable - 2.625 Percent Convertible Notes Due 2024 [Member]	Jan. 29, 2019$ / shares
Debt Instrument [Line Items]
Interest rate, stated percentage	2.625%
Conversion price (in dollars per share)	$ 88.80
Option indexed to issuer's equity, strike price (in dollars per share)	$ 114.92

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets (Goodwill) (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 618,042
Goodwill adjustment resulting from business acquisition	(1,009)
Foreign currency translation	(348)
Ending balance	$ 616,685

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets (Intangible Assets) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Intangible assets, Accumulated amortization	$ (239,966)		$ (239,966)		$ (222,938)
Intangible assets, Gross carrying amount	757,153		757,153		755,738
Amortization expense	8,500	$ 8,300	17,000	$ 15,700
Future amortization expense [Abstract]
Remaining, 2020	17,019		17,019
2021	33,449		33,449
2022	32,293		32,293
2023	31,516		31,516
2024	30,691		30,691
2025	30,947		30,947
Amortization included in expense
Future amortization expense [Abstract]
Remaining, 2020	14,019		14,019
2021	27,449		27,449
2022	26,293		26,293
2023	25,516		25,516
2024	24,691		24,691
2025	24,947		24,947
Amortization recorded as a reduction of revenue
Future amortization expense [Abstract]
Remaining, 2020	3,000		3,000
2021	6,000		6,000
2022	6,000		6,000
2023	6,000		6,000
2024	6,000		6,000
2025	6,000		6,000
Trademarks & tradenames
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Unamortized intangible assets, Gross carrying amount	86,544		86,544		86,544
Customer and distributor relationships
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Amortized intangible assets, Gross carrying amount	342,420		342,420		342,568
Intangible assets, Accumulated amortization	(124,865)		(124,865)		(115,311)
Sales representation, marketing and promotional rights
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Amortized intangible assets, Gross carrying amount	149,376		149,376		149,376
Intangible assets, Accumulated amortization	(51,000)		(51,000)		(48,000)
Patents and other intangible assets
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Amortized intangible assets, Gross carrying amount	72,209		72,209		70,646
Intangible assets, Accumulated amortization	(47,663)		(47,663)		(46,456)
Developed technology
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Amortized intangible assets, Gross carrying amount	106,604		106,604		106,604
Intangible assets, Accumulated amortization	(16,438)		(16,438)		$ (13,171)
Asset acquisition, contingent consideration liability	$ 6,000		$ 6,000
Weighted Average
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Finite-lived intangible asset useful life (in years)			22 years
Weighted Average | Customer and distributor relationships
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Finite-lived intangible asset useful life (in years)			24 years
Weighted Average | Sales representation, marketing and promotional rights
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Finite-lived intangible asset useful life (in years)			25 years
Weighted Average | Patents and other intangible assets
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Finite-lived intangible asset useful life (in years)			15 years
Weighted Average | Developed technology
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Finite-lived intangible asset useful life (in years)			16 years

Long Term Debt (Details)

Long Term Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Long-term Debt and Lease Obligation, Including Current Maturities	$ 805,618	$ 768,807
Finance Lease, Liability	743	836
Current portion of long-term debt	15,193	13,596
Long-term debt	790,425	755,211
Line of Credit [Member]
Debt Instrument [Line Items]
Long-term Debt	258,000	220,000
Term Loan Facility [Member]
Debt Instrument [Line Items]
Long-term Debt	246,740	253,535
Unamortized Debt Issuance Expense	1,697	1,528
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Convertible Debt	300,135	294,436
Debt Instrument, Unamortized Discount	38,502	43,312
Unamortized Debt Issuance Expense	$ 6,363	$ 7,252

Long Term Debt Additional Infor

Long Term Debt Additional Information (Details) - USD ($)	Jan. 29, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Feb. 07, 2019
Debt Instrument [Line Items]
Amortization of debt discount		$ 2,500,000	$ 2,300,000	$ 4,810,000	$ 3,774,000
Term Loan Facility [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross		248,400,000		248,400,000
Long-term Debt		246,740,000		246,740,000		$ 253,535,000
Term Loan Facility [Member] | Amended and Restated Senior Credit Agreement [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount							$ 265,000,000
Line of Credit [Member]
Debt Instrument [Line Items]
Long-term Debt		258,000,000		258,000,000		$ 220,000,000
Line of Credit Facility, Remaining Borrowing Capacity		324,500,000		324,500,000
Line of Credit [Member] | Amended and Restated Senior Credit Agreement [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity							585,000,000
Letter of Credit [Member]
Debt Instrument [Line Items]
Letters of Credit Outstanding, Amount		2,500,000		2,500,000
Convertible Notes Payable [Member] | 2.625 Percent Convertible Notes Due 2024 [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 345,000,000
Debt Instrument, Convertible, Carrying Amount of Equity Component	$ 39,100,000
Interest rate, stated percentage	2.625%
Credit Agreement Expiration Trigger Requirement, Convertible Note Outstanding Balance							$ 150,000,000
Debt Instrument, Interest Rate, Effective Percentage	6.14%
Interest Expense, Debt		$ 2,300,000	$ 2,300,000	$ 4,500,000	$ 3,800,000
Debt Instrument, Convertible, Gross Amount of Equity Component	$ 51,600,000
Debt Instrument, Convertible, Initial Conversion Rate	11.2608
Conversion price (in dollars per share)	$ 88.80
Option indexed to issuer's equity, strike price (in dollars per share)	$ 114.92
Long-term Debt [Member] | Amended and Restated Senior Credit Agreement [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Commitment Fee Percentage				0.50%
Debt Instrument, Interest Rate, Effective Percentage		4.50%		4.50%
LIBOR Interest Rate Floor				1.00%
London Interbank Offered Rate (LIBOR) [Member] | Long-term Debt [Member] | Amended and Restated Senior Credit Agreement [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate				3.50%
Fed Funds Effective Rate Overnight Index Swap Rate [Member] | Long-term Debt [Member] | Amended and Restated Senior Credit Agreement [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate				2.50%
Eurodollar [Member] | Long-term Debt [Member] | Amended and Restated Senior Credit Agreement [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate				3.50%
Call Option [Member]
Debt Instrument [Line Items]
Hedge and warrant transactions, net cash paid	$ 21,000,000

Long Term Debt Maturities of Lo

Long Term Debt Maturities of Long Term Debt (Details) $ in Thousands	Jun. 30, 2020USD ($)
Maturities of Long-term Debt [Abstract]
Remaining, 2020	$ 6,625
2021	18,219
2022	24,843
2023	456,750
2024	$ 345,000

Guarantees (Details)

Guarantees (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Guarantees [Abstract]
Standard warranty period (in years)	1 year
Movement in Standard Product Warranty Accrual [Roll Forward]
Balance as of January 1,	$ 2,186	$ 1,585
Provision for warranties	427	1,020
Claims made	(584)	(483)
Balance as of June 30,	2,029	2,122
Extended Product Warranty Disclosure [Abstract]
Product extended warranty expense	$ 3,000	$ 2,800

Pension Plan (Details)

Pension Plan (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Retirement Benefits [Abstract]
Service cost	$ 179	$ 253	$ 358	$ 506
Interest cost on projected benefit obligation	639	782	1,278	1,564
Expected return on plan assets	(1,255)	(1,181)	(2,510)	(2,362)
Net amortization and deferral	705	720	1,410	1,440
Net periodic pension cost	268	574	536	1,148
Defined Benefit Plan, Non-service cost	$ 100	$ 300	$ 200	$ 600

Acquisition and Other Expense_2

Acquisition and Other Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Acquisition and Other Expense [Line Items]
Restructuring costs	$ 3,200		$ 3,200
Assets Held-for-sale, Not Part of Disposal Group	3,000		3,000
Debt related commitment fees and debt issuance costs				$ 3,600
Other expense	89	$ 321	178	4,546
Loss on early extinguishment of debt			0	300
Restructuring Reserve	2,000		2,000
Cost of Sales
Acquisition and Other Expense [Line Items]
Plant underutilization cost	6,586	0	6,586	0
Product rationalization costs - inventory	2,169	0	2,169	0
Restructuring costs	1,087	0	1,087	0
Manufacturing consolidation costs	1,602	0	3,387	0
Acquisition and integration costs	652	503	1,457	1,163
Acquisition and other expense included in cost of sales or selling and administrative expense	12,096	503	14,686	1,163
Selling and Administrative Expenses
Acquisition and Other Expense [Line Items]
Restructuring costs	2,124	0	2,124	0
Product rationalization costs - field inventory	2,095	0	2,095	0
Acquisition and integration costs	439	2,461	1,192	9,706
Acquisition and other expense included in cost of sales or selling and administrative expense	4,658	2,461	5,411	9,706
Debt
Acquisition and Other Expense [Line Items]
Other expense	$ 0	$ 0	$ 0	$ 3,904

Business Segment (Details)

Business Segment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Segment Reporting Information [Line Items]
Net sales	$ 157,785	$ 238,263	$ 371,796	$ 456,641
Orthopedic Surgery
Segment Reporting Information [Line Items]
Net sales	60,483	115,757	159,766	229,194
General Surgery
Segment Reporting Information [Line Items]
Net sales	$ 97,302	$ 122,506	$ 212,030	$ 227,447

Legal Proceedings (Details)

Legal Proceedings (Details) - USD ($) $ in Millions	Jan. 18, 2017	Jun. 30, 2020
Loss Contingencies [Line Items]
Product liability insurance, amount per incident		$ 30
Product liability insurance, aggregate annual amount		$ 30
Pending Litigation | EndoDynamix, Inc.
Loss Contingencies [Line Items]
Loss Contingency, Damages Sought, Value	$ 12.7